Your browser is no longer supported. Please, upgrade your browser.
Settings
DEPO [NASD]
DepoMed Inc.
Index- P/E12.25 EPS (ttm)1.85 Insider Own0.40% Shs Outstand59.56M Perf Week-6.01%
Market Cap1.35B Forward P/E26.99 EPS next Y0.84 Insider Trans-35.33% Shs Float59.26M Perf Month0.31%
Income131.80M PEG0.41 EPS next Q0.01 Inst Own90.40% Short Float17.09% Perf Quarter45.88%
Sales390.40M P/S3.46 EPS this Y173.30% Inst Trans0.61% Short Ratio7.07 Perf Half Y50.93%
Book/sh6.18 P/B3.67 EPS next Y143.48% ROA25.20% Target Price24.50 Perf Year60.89%
Cash/sh9.39 P/C2.41 EPS next 5Y30.00% ROE61.90% 52W Range9.85 - 25.54 Perf YTD40.72%
Dividend- P/FCF- EPS past 5Y46.60% ROI25.60% 52W High-11.24% Beta1.25
Dividend %- Quick Ratio10.60 Sales past 5Y46.60% Gross Margin96.10% 52W Low130.15% ATR1.08
Employees324 Current Ratio10.70 Sales Q/Q379.30% Oper. Margin60.70% RSI (14)48.73 Volatility5.45% 4.56%
OptionableYes Debt/Eq0.67 EPS Q/Q70.80% Profit Margin38.30% Rel Volume0.66 Prev Close21.87
ShortableYes LT Debt/Eq0.67 EarningsMay 07 AMC Payout0.00% Avg Volume1.43M Price22.67
Recom2.30 SMA20-4.97% SMA508.00% SMA20041.67% Volume948,603 Change3.66%
Mar-13-15Downgrade WallachBeth Buy → Hold $28 → $26
Jan-16-15Upgrade ROTH Capital Neutral → Buy $25
Jan-16-15Reiterated RBC Capital Mkts Outperform $20 → $22
Dec-10-14Initiated RBC Capital Mkts Outperform $20
Jul-10-14Initiated WallachBeth Buy $17
Feb-25-13Downgrade WallachBeth Buy → Hold $8 → $7
Jan-05-12Initiated JMP Securities Mkt Outperform $8
Sep-30-11Initiated Auriga Buy $10
Feb-18-10Downgrade Merriman Buy → Neutral
Oct-21-09Initiated Caris & Company Buy $9
Oct-12-09Reiterated Merriman Buy $11.50 → $7.50
Oct-05-09Initiated Merriman Buy
Jun-20-08Initiated Roth Capital Buy $5
Mar-15-07Reiterated Thomas Weisel Overweight $8 → $6.50
Mar-17-15 08:32AM  Depomed Announces Termination of Hart-Scott-Rodino Waiting Period for Pending Acquisition of NUCYNTA® Franchise from Janssen Pharmaceuticals PR Newswire
Mar-13-15 07:16AM  DepoMed downgraded by WallachBeth
Mar-12-15 04:42PM  Depomed Secures $575 Million Debt Facility From Deerfield and Pharmakon to Finance the Closing of NUCYNTA® Acquisition at noodls
04:19PM  DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement
04:05PM  Depomed Secures $575 Million Debt Facility From Deerfield and Pharmakon to Finance the Closing of NUCYNTA® Acquisition PR Newswire
Mar-05-15 01:04PM  DEPOMED INC Financials
Mar-03-15 08:00AM  Depomed To Present At 27th Annual Roth Conference PR Newswire
Feb-28-15 07:08PM  10-K for Depomed, Inc. at Company Spotlight
Feb-26-15 06:12PM  DEPOMED INC Files SEC form 10-K, Annual Report
Feb-25-15 04:01PM  6 stocks to watch at MarketWatch
10:12AM  Depomed Reports Fourth Quarter and Full Year 2014 Financial Results at noodls
Feb-24-15 03:18PM  The Nasdaq is doing the most bullish thing a market can do at MarketWatch +10.78%
12:30PM  Depomed: The Next Big Specialty Pharma Success Story
10:36AM  Stocks Mixed As Yellen Speaks; Depomed, Home Depot, BHP Surge at Investor's Business Daily
Feb-23-15 04:31PM  Depomed tops 4Q revenue forecasts AP
04:30PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:01PM  Depomed Reports Fourth Quarter and Full Year 2014 Financial Results PR Newswire
07:07AM  Q4 2014 Depomed Inc Earnings Release - After Market Close CCBN
Feb-19-15 03:40PM  Two young stocks poised for a growth spurt at MarketWatch
Feb-12-15 08:00AM  Depomed To Report Fourth Quarter Fiscal Year 2014 Financial Results On Monday, February 23, 2015 PR Newswire
Feb-09-15 08:00AM  New American Headache Society Assessment of Acute Migraine Treatments Highlights Effective Therapies Based on Strength of Evidence PR Newswire
Feb-06-15 05:17PM  DEPOMED INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendment or Waiver to Code of Ethics EDGAR Online
Feb-04-15 08:00AM  Depomed To Present At Healthcare Conferences In February PR Newswire
Jan-20-15 09:00AM  East Bay's Depomed snags J&J pain-fighting drug in $1 billion deal at American City Business Journals -6.73%
Jan-16-15 04:34PM  U.S. markets break 5-day losing streak Yahoo Finance Contributors +14.45%
02:04PM  Mid-Day Market Update: U.S. Stocks Rise; SunTrust Shares Surge On Upbeat Earnings Benzinga
11:32AM  Depomed Hits High On Big Pain-Drug Deal With J&J at Investor's Business Daily
08:58AM  Depomed Surges 8% Following NUCYNTA Acquisition From Janssen Pharmaceuticals Benzinga
Jan-15-15 05:29PM  After-hours buzz: Intel, Regal, Depomed & more at CNBC
05:23PM  Depomed To Acquire Rights To NUCYNTA Franchise For $1.05 Billion Benzinga
05:21PM  DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial State EDGAR Online
05:00PM  Depomed Inc to Acquire the U.S. Rights to the NUCYNTA Franchise Call scheduled for 5:00 pm ET today CCBN
04:48PM  DepoMed to buy U.S. rights to Nucynta from J&J unit at MarketWatch
04:31PM  DepoMed to Buy U.S. Rights to Nucynta From J&J Unit at The Wall Street Journal
04:15PM  Depomed to pay $1 bln for J&J pain drug franchise Reuters
04:04PM  J&Js Pain Drug Is Depomeds Gain in $1.05 Billion Deal at Bloomberg
04:04PM  Depomed to Acquire U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) Oral Solution from Janssen Pharmaceuticals, Inc. for $1.05 billion PR Newswire
Nov-20-14 04:05PM  Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference PR Newswire
Nov-12-14 08:00AM  Depomed To Present At Stifel 2014 Healthcare Conference PR Newswire
Nov-08-14 07:07PM  10-Q for Depomed, Inc. Company Spotlight
Nov-06-14 04:28PM  DEPOMED INC Files SEC form 10-Q, Quarterly Report EDGAR Online
10:05AM  Another Solid Quarter For Depomed Zacks Small Cap Research
Nov-05-14 05:42PM  Depomed beats Street 3Q forecasts AP
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:11PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:05PM  Depomed Reports Third Quarter 2014 Financial Results PR Newswire
07:07AM  Q3 2014 Depomed Inc Earnings Release - After Market Close CCBN
Oct-27-14 04:01PM  Depomed To Report Third Quarter Fiscal Year 2014 Financial Results On Wednesday, November 5, 2014 PR Newswire
Oct-07-14 12:08PM  5 places to play momentum at MarketWatch
Oct-03-14 12:00AM  OxyContin, Cialis Makers Dodge Court to Beat Patent Suits at Bloomberg
Oct-01-14 11:14AM  [video] Dan Tana's: Hollywood's Iconic Red-Sauce Joint at MarketWatch
Sep-30-14 02:54PM  Accelerated selling means its time to move to cash at MarketWatch
Sep-17-14 04:07PM  DEPOMED INC Files SEC form 8-K, Other Events EDGAR Online
Sep-09-14 04:05PM  DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Ex EDGAR Online
Sep-05-14 05:00PM  DEPOMED INC Files SEC form 8-K, Other Events EDGAR Online
02:34PM  Depomed Summary Judgment Motion Granted in Suit against FDA Seeking Orphan Drug Exclusivity for Gralise® (Gabapentin) PR Newswire
Sep-04-14 07:38AM  DEPOMED INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
07:00AM  Depomed Announces Pricing of Upsized $300 Million Convertible Senior Notes Due 2021 PR Newswire
Sep-02-14 04:18PM  DEPOMED INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
04:00PM  Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 PR Newswire
Aug-25-14 04:01PM  Depomed To Present At Morgan Stanley 2014 Global Healthcare Conference PR Newswire
Aug-21-14 04:02PM  DEPOMED INC Files SEC form 8-K, Other Events EDGAR Online
Aug-19-14 04:35PM  Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs Benzinga +13.53%
04:03PM  Nasdaq stocks posting largest percentage increases AP
11:32AM  Why DepoMed (DEPO) Stock Is Gaining Today at TheStreet
11:15AM  Depomed Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024 PR Newswire
Aug-06-14 04:43PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:05PM  Depomed Reports Second Quarter 2014 Financial Results PR Newswire
07:07AM  Q2 2014 Depomed Earnings Release - After Market Close CCBN
Aug-04-14 05:08PM  DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
04:01PM  Depomed Announces Appointment of R. Scott Shively as Chief Commercial Officer PR Newswire
Jul-25-14 04:01PM  Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 PR Newswire
Jul-17-14 05:27PM  DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events EDGAR Online
05:15PM  2 Small-Cap Stocks Hedge Funds Love at Motley Fool
03:38PM  Depomed Announces District Court Order in ANDA Litigation PR Newswire
Jul-16-14 08:03AM  Depomed appoints Srinivas Rao as Chief Medical Officer theflyonthewall.com
08:00AM  Depomed Announces Appointment of Srinivas G. Rao, MD, PhD, as Chief Medical Officer PR Newswire
Jul-09-14 09:04AM  Immune Pharma: A Top-Pick Based On Pipeline And Valuation at Seeking Alpha
Jun-27-14 06:03PM  Martin Marietta Materials Set to Join the S&P 500; United States Steel Corp. Set to Join the S&P MidCap 400 and Depomed Inc. Set to Join the S&P SmallCap 600 PR Newswire
Jun-20-14 04:06PM  DEPOMED INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Jun-18-14 09:37AM  Exclusive: Steven Burrill Removed From Control Of Venture Fund For Unauthorized Payments at Forbes
08:00AM  Depomed To Present AT JMP Securities 2014 Healthcare Conference PR Newswire
Jun-10-14 11:00AM  TBUFF: A Pharmaceutical Company With Strong Upside Potential Zacks Small Cap Research
08:00AM  Depomed to Present at Wells Fargo 2014 Healthcare Conference PR Newswire
May-28-14 08:14AM  Mallinckrodt's NDA accepted by FDA, triggering $5M payment to Depomed at theflyonthewall.com
08:10AM  Mallinckrodt New Drug Application For MNK-155 Accepted For Review By FDA PR Newswire
May-27-14 04:05PM  Depomed To Present At Jefferies 2014 Global Healthcare Conference PR Newswire
May-23-14 05:07PM  DEPOMED INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Securit EDGAR Online
May-13-14 10:03AM  Perilous Reversal Stock: DepoMed (DEPO) at TheStreet -5.58%
May-12-14 09:51AM  DepoMed (DEPO) Is Today's Dead Cat Bounce Stock at TheStreet +13.53%
May-09-14 04:36PM  DEPOMED INC Files SEC form 10-Q, Quarterly Report EDGAR Online -15.64%
04:01PM  Depomed To Present At Bank of America Merrill Lynch Healthcare Conference And UBS Global Healthcare Conference PR Newswire
03:40PM  Review Of Depomed's First Quarter Results - Mind The GAAP at Seeking Alpha
01:12PM  Why DepoMed Inc. Shares Were Rocked at Motley Fool
May-08-14 08:00PM  DepoMed's (DEPO) CEO James Schoeneck on Q1 2014 Results - Earnings Call Transcript at Seeking Alpha -9.27%
05:00PM  Depomed Earnings Call scheduled for 5:00 pm ET today CCBN
04:30PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:19PM  Depomed sees FY14 adjusted EPS 0c-16c, one estimate 31c at theflyonthewall.com
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. The company also has a portfolio of royalty and milestone producing license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vargas Thadd MSenior VP, BDJan 20Option Exercise5.0319,00095,57088,443Jan 22 06:28 PM
Schoeneck James APresident and CEODec 19Option Exercise8.3640,700340,25256,432Dec 22 09:14 AM
Gosling Matthew MSenior VP, General CounselDec 02Sale15.858,819139,80832,501Dec 03 05:36 PM
Schoeneck James APresident and CEODec 02Sale15.8536,727582,23352,930Dec 03 05:35 PM
Vargas Thadd MSenior VP, BDDec 02Sale15.858,247130,74069,443Dec 03 05:35 PM
Moretti August JChief Financial OfficerDec 02Sale15.855,33984,63922,564Dec 03 05:35 PM
STAPLE PETER DDirectorNov 25Option Exercise5.0410,00050,40050,000Nov 26 04:38 PM
Gosling Matthew MSenior VP, General CounselNov 19Option Exercise6.1771,000438,07088,211Nov 21 08:00 PM
Gosling Matthew MSenior VP, General CounselNov 19Sale15.3671,0001,090,34717,211Nov 21 08:00 PM
Schoeneck James APresident and CEOAug 01Option Exercise6.1130,000183,30042,898Aug 04 10:46 AM
Vargas Thadd MSenior VP, BDMay 16Option Exercise3.0939,040120,63453,119May 19 05:34 PM
Gosling Matthew MSenior VP, General CounselMay 09Option Exercise6.174,00024,68015,396May 09 07:37 PM
Schoeneck James APresident and CEOMay 09Option Exercise4.5330,000135,750126,306May 09 07:37 PM